Targeted Genetics Corporation Updates Investors on Annual Meeting Matters

SEATTLE--(BUSINESS WIRE)-- Targeted Genetics Corporation (Pink Sheets:TGEN), or the Company, today announced that the Superior Court of the State of Washington issued an order authorizing the Company to set the record date for the Company’s next Annual Meeting on a date consistent with the Company’s bylaws and Washington law. This ruling follows the Company’s request that the Court reconsider its prior order resetting the record date for the Company’s next Annual Meeting from December 10, 2010 to December 2, 2010.

In accordance with the Court’s order, the Company’s bylaws, and applicable Washington law, the Company has fixed the close of business on January 19, 2011 as the record date for the Company’s next Annual Meeting, and has rescheduled the date of the Annual Meeting from January 27, 2011 to February 18, 2011, in order to comply with certain timing requirements of the Company’s bylaws.

Notes to Editors

About Targeted Genetics Corporation

Targeted Genetics Corporation is a biotechnology company committed to the development and commercialization of innovative therapies for the prevention and treatment of diseases with significant unmet medical need. To learn more about Targeted Genetics, visit Targeted Genetics' website at www.targetedgenetics.com.



CONTACT:

Targeted Genetics Corporation
David Poston, CFO & Company Secretary
+1 (206) 623-7612

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.